Medtronic plc launched a new breakthrough device for the treatment of tricuspid valve regurgitation. The Intrepid Transcatheter Tricuspid Valve Replacement (TTVR) system is helpful for the patients with severe, symptomatic tricuspid regurgitation.
Tricuspid regurgitation disease is caused when damage or malfunctioning tricuspid valve allows the flow of blood in reverse direction into the heart’s upper right chamber resulting in heart failure or death. More than two million patients in the US alone experience tricuspid regurgitation. Due to the morbidity and mortality risks related with surgical intervention the disease is untreated.
The Intrepid transcatheter valve is the similar valve being evaluated for the treatment of symptomatic mitral valve regurgitation in the transfemoral mitral early feasibility study. The device is implanted using a transfemoral delivery catheter, which further helps physicians in assisting, delivering and placing the valve through a catheter inserted in the femoral vein.
U.S. Food and Drug Administration (FDA) grants Breakthrough Device Designation Early Feasibility Study for Investigational Intrepid™ Transcatheter Valve System for the Treatment of Tricuspid Valve Regurgitation.